Hepatitis C ‘Me-Too’ Drugs: Innovation and Lower Cost

UF Researchers Make Breakthrough in Multiple Sclerosis Research
October 16, 2017
ACA Medicaid Expansion Cut Disparities in Cancer Care for Minorities, Poor
October 16, 2017
Show all

Hepatitis C ‘Me-Too’ Drugs: Innovation and Lower Cost

Treating hepatitis C might come at a lower cost in the future.

I have written frequently about hepatitis C. First, during my former career in drug discovery research, I spent 10 futile, frustrating years working in this area. Second, the quarter-century campaign that led to a cure for the infection is unquestionably one of the most impressive accomplishments in the history of medicinal chemistry (1).

I have also written about the benefit of second- and third-generation drugs, which are dismissed as “me-too” drugs by know-nothing critics of the industry, such as Sidney Wolfe and Marcia Angell. Ignorant critics would have you believe that the fourth approved drug in a class is nothing more than a non-innovative cash cow for drug companies. They could hardly be more wrong.

It is now clear that patients benefit greatly when there are multiple choices of drugs for a particular ailment; not just medically, but also economically. There can be no better example of this than AbbVie’s Mavyretthe newest weapon in the already-impressive arsenal against hepatitis C—a pernicious virus that has infected 3 million people in the US and 170 million worldwide.

Read full article: Hepatitis C ‘Me-Too’ Drugs: Innovation and Lower Cost | American Council on Science and Health

Read Full Article: Hepatitis C ‘Me-Too’ Drugs: Innovation and Lower Cost | American Council on Science and Health

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.